MacroGenics (MGNX)
(Delayed Data from NSDQ)
$3.58 USD
-0.25 (-6.53%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $3.58 0.00 (0.00%) 6:36 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
MacroGenics, Inc. [MGNX]
Reports for Purchase
Showing records 281 - 300 ( 362 total )
Company: MacroGenics, Inc.
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 25th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MacroGenics, Inc.
Industry: Medical - Products
Week Ahead in Life Sciences - Upcoming Events for the Week of May 18th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Rich Pipeline Continues to Advance; Early ''271 Data in H2:15, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
1Q15 Takeaways; Robust Pipeline and Clinical Program Growth
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 4th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MacroGenics, Inc.
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 27th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Advantage DART''s as Preliminary Solid Tumor CAR-T Underwhelms
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Healthcare -Biotechnology: Catalyst Tracker Through Mid-15
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Healthcare: Biotechnology: Its Yogi Berra All Over Again
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
First Peek at Future DART Targets from the AACR-15
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Third DART Candidate Advances to Clinic for Treatment of Autoimmune Disorders
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Another Day and Another DART Heads to the Clinic
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Healthcare - Biotechnology: Key Takeaways From the 27th Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MGNX''s Third DART Candidate Advances to Clinic for Treatment of Autoimmune Disorders
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.